Identifying immune markers to predict long-term effects of Lyme disease
Official title: Discovery of early immunologic biomarkers for risk of PTLDS through machine learning-assisted broad temporal profiling of humoral immune response
Funded at Arizona State University-Tempe Campus · NIH-10884335 · Data updated 2026-11-12
This study is looking for ways to spot early signs in your immune system that could help predict if you might develop lingering symptoms after being treated for Lyme disease, so you can get the right care sooner.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project start | July 7, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $624,294 |
| NIH project number | 5R01AI178727-02 |
| Project ID | NIH-10884335 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Lyme disease who are undergoing treatment.
✕Less likely to help
Patients who have not been diagnosed with Lyme disease or those who have already developed PTLDS may not benefit from this research.
What this research studies
This research investigates how to identify early immunologic biomarkers that can predict the risk of developing Post Treatment Lyme Disease Syndrome (PTLDS) in patients who have been treated for Lyme disease. By utilizing machine learning techniques, the study aims to analyze the humoral immune response during the acute phase of Lyme disease. The goal is to provide early risk assessments that can help guide treatment decisions and improve patient outcomes. This approach seeks to address the current lack of approved diagnostic tests for PTLDS, which often leaves patients without adequate care options.
Why it matters
Potential benefit: If successful, this research could lead to earlier interventions for patients at risk of developing PTLDS, potentially improving their quality of life and treatment outcomes.
How similar studies have gone: While the approach of using immunologic biomarkers for early risk assessment is promising, it is still largely untested in the context of PTLDS, making this research novel.
Where this research is happening
-
Arizona State University-Tempe Campus
Tempe, United States Active
Researchers
- Principal investigator: Woodbury, Neal Walter — Arizona State University-Tempe Campus
- Study coordinator: Woodbury, Neal Walter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.